ID   ASH-3
AC   CVCL_2856
SY   ASH3
DR   CLO; CLO_0037151
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03470933
DR   cancercelllines; CVCL_2856
DR   Cell_Model_Passport; SIDM00491
DR   Cosmic; 2054110
DR   Cosmic-CLP; 1290722
DR   DepMap; ACH-001443
DR   EGA; EGAS00001000978
DR   GDSC; 1290722
DR   GEO; GSM827189
DR   GEO; GSM1669602
DR   JCRB; JCRB1073
DR   JCRB; NIHS0269
DR   LINCS_LDP; LCL-1682
DR   PharmacoDB; ASH3_65_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_2856
DR   Wikidata; Q54750715
RX   PubMed=11686581;
RX   PubMed=20215515;
RX   PubMed=23833040;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=30737244;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 84 hours (PubMed=11686581); 43-47 hours (Note=Lot 12072015) (JCRB=JCRB1073).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=23833040).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.181A>G); Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Phe241fs (c.724dupG); Zygosity=Homozygous (PubMed=30737244; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Homozygous (PubMed=30737244; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.08%; East Asian, North=79.16%; East Asian, South=20.41%; South Asian=0.34%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0269; true.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): Cosmic-CLP; DepMap; JCRB; PubMed=25877200; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 10,14
ST   D13S317: 12
ST   D16S539: 9
ST   D18S51: 13,17
ST   D19S433: 13,15.2
ST   D21S11: 28
ST   D2S1338: 19,23
ST   D3S1358: 15
ST   D5S818: 11,13
ST   D7S820: 11
ST   D8S1179: 16
ST   FGA: 20,22
ST   Penta D: 10,11
ST   Penta E: 5
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   68Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 32
//
RX   PubMed=11686581; DOI=10.1016/S0753-3322(01)00087-7;
RA   Sekiguchi M., Shiroko Y., Arai T., Kishino T., Sugawara I.,
RA   Kusakabe T., Suzuki T., Yamashita T., Obara T., Ito K., Hasumi K.;
RT   "Biological characteristics and chemosensitivity profile of four human
RT   anaplastic thyroid carcinoma cell lines.";
RL   Biomed. Pharmacother. 55:466-474(2001).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//